Gary Bloomgren
About Gary Bloomgren
Gary Bloomgren is the Vice President of Drug Safety and Pharmacovigilance at Alkermes, with over 25 years of experience in global clinical research and development.
Current Role at Alkermes
Gary Bloomgren currently serves as Vice President of Drug Safety and Pharmacovigilance at Alkermes in Waltham, Massachusetts. He started this role in October 2016. At Alkermes, he is responsible for overseeing drug safety protocols and ensuring pharmacovigilance across the company's therapeutic programs. His role is pivotal in maintaining the safety of drugs and ensuring regulatory compliance.
Previous Role at Biogen Idec
Gary Bloomgren worked at Biogen Idec as Vice President of Drug Safety and Risk Management from 2010 to 2016. During his six years in Cambridge, Massachusetts, he led the Drug Safety and Risk Management team, focusing on identifying and mitigating risks associated with pharmaceutical products. His contributions were significant in maintaining drug safety standards and streamlining risk management processes.
Executive Director at Amylin Pharmaceuticals
From 2003 to 2010, Gary Bloomgren served as Executive Director at Amylin Pharmaceuticals in San Diego, California. Over his seven-year tenure, he held a leadership position where he contributed to the development and safety assessment of various pharmaceutical products, playing a crucial role in the company's drug safety initiatives.
Educational Background in Medicine and Business
Gary Bloomgren obtained his Doctor of Medicine (M.D.) degree from Baylor College of Medicine, where he studied Internal Medicine from 1981 to 1985. He then pursued an MBA at the University of Utah - David Eccles School of Business, graduating in 1993. His extensive education in both medicine and business has equipped him with a unique perspective in managing drug safety and pharmacovigilance.
Industry Experience and Leadership Positions
With over 20 years in drug safety and pharmacovigilance, Gary Bloomgren has accumulated extensive experience across various leadership roles. He has held positions at companies such as Vertex Pharmaceuticals, TARIS Biomedical, Coley Pharmaceutical Group, and Millennium Pharmaceuticals. He also served as Vice President and Head of Clinical Sciences, Rare Genetics, and Hematology at Takeda Pharmaceutical Company, showcasing his expertise in clinical research and development.